FDA Pulmonary-Allergy Drugs Advisory Committee
Schering's non-sedating antihistamine loratidine will be reviewed on the second day of the panel's Oct. 22-23 meeting. First-day agenda items include: surfactant replacement therapy; effect of theophylline on school performance; rationality of antitussive-expectorant combos; and adverse reaction of beta-agonists. Meeting will be held in FDA's Parklawn Building, Conference Rooms G&H beginning at 8:30 A.M. both days.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.